AL

Theradiag SAPAR Theradiag Stock Report

Last reporting period 30 Jun, 2020

Updated —

Last price

Market cap $B

0.013

Micro

Exchange

XPAR - Euronext Paris

ALTER.PA Stock Analysis

AL

Uncovered

Theradiag SA is uncovered by Eyestock quantitative analysis.

Market cap $B

0.013

Dividend yield

Shares outstanding

13.013 B

Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.

View Section: Eyestock Rating